Skip to main content
Cantargia logo

Cantargia — Investor Relations & Filings

Ticker · CANTA ISIN · SE0023312970 LEI · 549300GKWRT7RXI4VS85 ST Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2022-05-26 Regulatory Filings
Country SE Sweden
Listing ST CANTA

About Cantargia

https://cantargia.com/en/

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Recent filings

Filing Released Lang Actions
Cantargia presents clinical interim results at ASCO 2022 highlighting the potential of nadunolimab in combination with checkpoint inhibitor
Regulatory Filings Classification · 99% confidence The document is a press release announcing 'new results from the phase Ib clinical trial CIRIFOUR' and stating that these results 'will be presented at the ASCO 2022 Annual Meeting'. It details clinical interim results, safety profiles, and biomarker findings related to their drug nadunolimab. This content is characteristic of an initial announcement of periodic financial or operational results, focusing on key highlights (clinical trial progress in this case) rather than a comprehensive report (like a 10-K or IR). Since it is an initial announcement of results, the most appropriate classification is 'Earnings Release' (ER), as this category often encompasses key operational/clinical updates released periodically, especially when they are not the full, detailed report itself. It is not a Call Transcript (CT), Investor Presentation (IP), or a comprehensive Interim Report (IR).
2022-05-26 English
Cantargia presenterar nya robusta data på ASCO 2022 som bekräftar lovande effekter av nadunolimab vid behandling av bukspottkörtelcancer
Regulatory Filings Classification · 99% confidence The document is a 'Pressmeddelande' (Press Release) from Cantargia AB dated May 26, 2022. It announces the presentation of new clinical data for their drug nadunolimab at the ASCO 2022 conference on June 4, 2022. The text details interim results (median overall survival, progression-free survival, safety profile) from the CANFOUR Phase I/IIa study in pancreatic cancer patients. This type of announcement, which summarizes key financial/clinical results and points to a future presentation or publication, is characteristic of an Earnings Release (ER) or a general announcement. Since it is a press release announcing key clinical trial results and updates, it fits best under 'Earnings Release' (ER) as it communicates period results, even if clinical rather than purely financial. It is not a full report (10-K, IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV. It is an announcement of results, making ER the most appropriate fit among the provided options, although it could also be considered a Regulatory Filing (RNS) if ER was too narrow. Given the focus on 'interimsresultat' (interim results) and the date of the announcement coinciding with the data presentation, ER is selected.
2022-05-26 Swedish
Årsstämma i Cantargia AB (publ)
AGM Information Classification · 99% confidence The document is explicitly titled "Årsstämma i Cantargia AB (publ)" which translates to "Annual General Meeting in Cantargia AB (publ)". The content details decisions made during this meeting, such as dividend decisions, re-election of board members, auditor appointment, and approval of incentive programs and share issuance authorizations. These items are characteristic of the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the correct classification is AGM Information (AGM-R). The document length is relatively short (2555 chars), but it contains the substantive decisions, not just an announcement that the meeting occurred or that minutes are available, making AGM-R more specific than RPA or RNS.
2022-05-23 Swedish
Annual General Meeting in Cantargia AB (publ)
AGM Information Classification · 99% confidence The document explicitly states 'Annual General Meeting in Cantargia AB (publ)' and details the resolutions passed during this meeting, such as dividend decisions, board re-elections, auditor re-election, and approval of incentive schemes. This content directly corresponds to the materials presented or finalized at an AGM. Therefore, the appropriate classification is AGM Information (AGM-R). The document length is relatively short (2671 chars), but it contains the substance of the meeting outcomes, not just an announcement that the meeting occurred or that materials are available, making AGM-R more specific than RPA or RNS.
2022-05-23 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'DELÅRSRAPPORT' (Interim Report) for the period January-March 2022. It contains comprehensive financial data, including income statements, balance sheet items (net sales, operating results, liquidity), and detailed management commentary on business trends, clinical trial progress, and future outlook. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2022
2022-05-23 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT' and covers the period 'January - March 2022'. It contains detailed financial data (Net sales, operating loss, loss per share, cash equivalents) and a comprehensive review of business operations, clinical trials, and management commentary. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2022
2022-05-23 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.